JTK-109

• Description:

  JTK-109 is a potent inhibitor of hepatitis C virus NS5B RNA-dependent RNA polymerase. JTK-109 has NS5B inhibitory activity with IC50 value of 0.017μM. JTK-109 can be used for the research of hepatitis C virus (HCV) [1].

• UNSPSC:

  12352005

• Target:

  HCV Protease

• Type:

  Reference compound

• Related Pathways:

  Anti-infection; Metabolic Enzyme/Protease

• Applications:

  COVID-19-anti-virus

• Field of Research:

  Infection

• Assay Protocol:

  https://www.medchemexpress.com/jtk-109.html

• Purity:

  98.68

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C(C1=CC=C2C(N=C(C3=CC=C(OCC4=CC(N5C(CCC5)=O)=CC=C4C6=CC=C(Cl)C=C6)C=C3F)N2C7CCCCC7)=C1)O

• Molecular Formula:

  C37H33ClFN3O4

• Molecular Weight:

  638.13

• References & Citations:

  [1]Hirashima S, et al. Further studies on hepatitis C virus NS5B RNA-dependent RNA polymerase inhibitors toward improved replicon cell activities: benzimidazole and structurally related compounds bearing the 2-morpholinophenyl moiety. Bioorg Med Chem Lett. 2007 Jun 1;17 (11) :3181-6.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Phase 1

• CAS Number:

  480462-62-2